Delcath Systems, Inc. (DCTH) - NASDAQ
  • Jun. 10, 2015, 12:53 PM
    | Jun. 10, 2015, 12:53 PM | 3 Comments
  • Jun. 1, 2015, 9:21 AM
    | Jun. 1, 2015, 9:21 AM | 4 Comments
  • May 29, 2015, 10:23 AM
    • Delcath Systems (DCTH +32.8%) moves up on a 10x surge in volume in response to an online abstract presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
    • The abstract, "Single Centre Experience of Chemosaturation Percutaneous Hepatic Perfusion in the Treatment of Metastatic Uveal Melanoma," relates to data from 20 patients with ocular melanoma who each received 1-3 treatments with the company's percutaneous hepatic perfusion therapy CHEMOSAT. Two patients showed stable disease for more than three months, 13 had a partial response in the liver and two had a complete response. Nine deaths from cancer progression occurred after a median of 264 days from the date of the first procedure. 11 patients remain alive after a median of 280 days with one complete response ongoing after more than one year. From the diagnosis of liver metastases, 11 patients have survived one year and three for more than two years.
    • Uveal melanoma, also known as ocular melanoma, is a rare cancer of the eye with a very poor prognosis. Half of the patients develop metastases, the vast majority (90%) in the liver. Mean survival is only six months. The one-year survival rate is 15 - 20%.
    • CHEMOSAT is high dose chemotherapy (melphalan) that is directly perfused into the liver via a catheter. It is CE Mark-approved in Europe but still experimental in the U.S.
    | May 29, 2015, 10:23 AM
  • May 29, 2015, 9:14 AM
    | May 29, 2015, 9:14 AM | 5 Comments
  • May 28, 2015, 12:47 PM
    | May 28, 2015, 12:47 PM | 2 Comments
  • Feb. 11, 2015, 12:45 PM
    | Feb. 11, 2015, 12:45 PM
  • Feb. 11, 2015, 10:22 AM
    • Thinly-traded nano cap Delcath Systems (DCTH -23.5%) plummets on an 11x surge in volume in response to its public offering of 2.460M shares of common stock and warrants to purchase up to 1.107M shares of common stock at a combined price of $1.15. The exercise price of the warrants is $1.38. Closing date is February 17.
    • Net proceeds of ~$2.4M will fund clinical trials, ongoing operations and general corporate purposes.
    | Feb. 11, 2015, 10:22 AM
  • Feb. 11, 2015, 9:13 AM
    | Feb. 11, 2015, 9:13 AM | 7 Comments
  • Jan. 9, 2015, 12:47 PM
    | Jan. 9, 2015, 12:47 PM | 2 Comments
  • Sep. 3, 2014, 2:07 PM
    • Shares of thinly-traded nano cap Delcath Systems (DCTH -3.5%) ease up today on increased volume. Shares rose 7% yesterday after activist shareholder Linkedto Partners called for management to cut their hefty salaries in order to save money and pursue an immediate sale of the firm considering its substantial cash burn and scant revenues.
    • Whether or not management listens to Linedto Partners is unknown. Its position is only 77K shares which represents a modest 0.8% stake.
    | Sep. 3, 2014, 2:07 PM | 10 Comments
  • Apr. 10, 2014, 12:45 PM
    | Apr. 10, 2014, 12:45 PM | 3 Comments
  • Dec. 13, 2013, 2:19 PM
    • Delcath's (DCTH -4.9%) board has filed proxy materials requesting shareholders allow it to carry out a reverse split. Shareholders will vote on the matter at a Feb. 24 special meeting. (PR)
    • Separately, the Nasdaq has granted Delcath a 180-day extension to regain compliance with its minimum bid price rule. A reverse split would allow Delcath to meet the Nasdaq's $1/share requirement.
    | Dec. 13, 2013, 2:19 PM | 4 Comments
  • Oct. 23, 2013, 9:20 AM
    • Delcath Systems (DCTH) says it is raising around $7.5M in an offering of nearly 21M shares and warrants (exercise price is $0.44) for up to 9.432M shares.
    • Price is $0.36/share and related warrant. (PR)
    • DCTH -19% premarket
    | Oct. 23, 2013, 9:20 AM | 3 Comments
  • Oct. 2, 2013, 11:00 AM
    • Delcath Systems (DCTH +67.2%) is up sharply in morning trading, apparently on news the FDA has granted an Orphan designation for melphalan hydrochloride in hepatocellular carcinoma.
    • The punchline: It actually happened last week.
    | Oct. 2, 2013, 11:00 AM | 1 Comment
  • May 8, 2013, 5:22 PM

    More on Delcath Systems (DCTH): Q1 comes up short on a per share basis but beats on the revenue side. Most of the revenue gain was related to the recognition of previously deferred revenue as a result of satisfying certain requirements of the its Research and Distribution agreement with Chi-Fu Trading in Taiwan, while the remainder was from product sales. SG&A and R&D expenses both declined, primarily due to a significant reduction in expenses related to the its New Drug Application submission to the FDA. Shares -4% AH.

    | May 8, 2013, 5:22 PM
  • May 8, 2013, 5:21 PM
    Delcath (DCTH): Q1 EPS loss of -$0.15 misses by $0.02. Revenue of $400K (+42% Y/Y) beats by $120K. (PR). Shares -4% AH.
    | May 8, 2013, 5:21 PM
Company Description
Delcath Systems, Inc. is a pharmaceutical and medical device company, which is focused on oncology and liver cancer therapy. Its proprietary drug and device combination product, Delcath Hepatic Delivery System is designed to administer high dose chemotherapy and other therapeutic agents to the... More
Sector: Healthcare
Industry: Drug Delivery & Accessories
Country: United States